Overview
Mynd Therapeutics develops next-generation psychedelic-derived compounds targeting treatment-resistant depression and PTSD through precision neurochemistry.
More in Neuropharmaceuticals
Latest industry news
Austin Brain Implant Lets Patient Communicate in Real Time: 'I Have a Lot to Say'
2026-09-14 · Research
ReVision Implant Secures €4 Million to Push Visual Neuroprosthetics Forward
2026-09-13 · Funding
Flourish Emerges From Stealth With Bezos and Google Ventures Backing to Reimagine Neuroscience
2026-09-12 · Funding
Grand View Research Maps the BCI Packaging Market Through 2033 as Hardware Complexity Grows
2026-09-11 · Industry
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →